Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;1998(2):CD000953.
doi: 10.1002/14651858.CD000953.

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

J Pope  1 , D Fenlon, A Thompson, B Shea, D Furst, G Wells, A Silman
Affiliations

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

J Pope et al. Cochrane Database Syst Rev. 2000.

Abstract

Objectives: To assess the effects and toxicity of the following agents:Prostaglandin analogues together with other agents proposed for the treatment of Raynaud's phenomenom (RP) in scleroderma.

Search strategy: We searched the Cochrane Controlled Trials Register, and Medline up to 1996 using the Cochrane Collaboration search strategy developed by Dickersin et al.(1994). Key words included: raynaud's or vasospasm, scleroderma or progressive systemic sclerosis or connective tissue disease or autoimmune disease. Current Contents were searched up to and including April 7, 1997. All bibliographies of articles retrieved were searched and key experts in the area were contacted for additional and unpublished data. The initial search strategy included all languages.

Selection criteria: All randomized controlled trials comparing prostaglandin analogues versus placebo were eligible if they reported clinical outcomes within the start of therapy, and if the dropout rate was less than 35%.

Data collection and analysis: Data were abstracted independently by two reviewers (DF, AT). Peto's odds ratios were calculated for all dichotomous outcomes and a weighted mean difference was calculated for all continuous outcomes. A fixed effects or random effects model was used if the data were homogeneous or heterogeneous, respectively.

Main results: Seven randomized trials and 332 patients were included. Five of the seven trials were of parallel design. Five trials compared I.V. Iloprost and one trial studied p.o. Iloprost and another p.o. Cisaprost. Some trials were dose finding trials so various doses of Iloprost were used. Due to different efficacies of I.V. Iloprost, oral Iloprost and oral Cisaprost, the overall efficacy of these drugs was somewhat diluted. Intravenous Iloprost appears to be effective in the treatment of secondary Raynaud's phenomenon.

Reviewer's conclusions: Intravenous Iloprost is effective in the treatment of Raynaud's phenomenon secondary to scleroderma at decreasing the frequency and severity of attacks and preventing or healing digital ulcers. The effect seems to be prolonged after the intravenous infusion is given. Oral Iloprost may have less efficacy than intravenous Iloprost. However, Cisaprost has minimal or no efficacy when given orally for the treatment of Raynaud's phenomenon secondary to scleroderma.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Prostacyclin analogues, Outcome 1 Iloprost vs. Placebo.
1.2
1.2. Analysis
Comparison 1 Prostacyclin analogues, Outcome 2 Cisaprost 2.5 ug vs. Placebo.
2.1
2.1. Analysis
Comparison 2 Iloprost vs. Placebo (Change from baseline), Outcome 1 Sign and Symptom Likert Score.
2.2
2.2. Analysis
Comparison 2 Iloprost vs. Placebo (Change from baseline), Outcome 2 Average Duration of Attacks.
2.3
2.3. Analysis
Comparison 2 Iloprost vs. Placebo (Change from baseline), Outcome 3 Severity Score.
2.4
2.4. Analysis
Comparison 2 Iloprost vs. Placebo (Change from baseline), Outcome 4 frequency of attacks.
3.1
3.1. Analysis
Comparison 3 Prostacyclin analogues, Outcome 1 Iloprost vs. Placebo (IV infusions only).
4.1
4.1. Analysis
Comparison 4 Prostacyclin analogues, Outcome 1 Oral Iloprost vs. Placebo.
See this image and copyright information in PMC

References

References to studies included in this review

Belch 1995 {published data only}
    1. Belch JJ, Capell HA. Cooke ED.Kirby JD.Lau CS.Madhok R.Murphy E. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Annals of the Rheumatic Diseases 1995;54(3):197‐200. - PMC - PubMed
Kyle 1992 {published data only}
    1. Kyle MV, Belcher G, Hazleman BL. Placebo Controlled Study Showing Therapeutic Benefit of Iloprost in the Treatment of Raynaud's Phenomenon. Journal of Rheumatology 1992;19:1403‐6. - PubMed
Lau 1993 {published data only}
    1. Lau CS, Belch JJ. Madhok R.Cappell H.Herrick A.Jayson M.Thompson JM. A randomised, double‐blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clinical & Experimental Rheuma tology 1993;11(1):35‐40. - PubMed
McHugh 1988 {published data only}
    1. McHugh NJ, Csuka M. Watson H.Belcher G.Amadi A.Ring EF.Black CM. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Annals of the Rheumatic Diseases 1988;47(1):43‐7. - PMC - PubMed
Wigley 1992 {published data only}
    1. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Journal of Rheumatology 1992;19(9):1407‐14. - PubMed
Wigley 1994 {published data only}
    1. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Jr, Steen VD, Varga J, Jimenez S, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo‐controlled, double‐blind study. Annals of Internal Medicine 1994;120(3):199‐206. - PubMed
Yardumian 1988 {published data only}
    1. Yardumian DA, Isenberg DA. Rustin M.Belcher G.Snaith ML.Dowd PM.Machin SJ. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. British Journal of Rheumatology 1988;27(3):220‐6. - PubMed

References to studies excluded from this review

Belch 1983 {published data only}
    1. Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double‐blind controlled trial. Lancet 1983;1(8320):313‐5. - PubMed
Lau 1991 {published data only}
    1. Lau CS, McLaren M. Saniabadi A.Scott N.Belch JJ. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis‐‐a preliminary study. Clinical & Experimental Rheumatology 1991;9(3):271‐3. - PubMed
McCune 1983 {published data only}
    1. McCune MA, Winkelmann RK. Osmundson PJ.Pineda AA. Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma. Journal of Clinical Apheresis 1983;1(4):206‐14. - PubMed
Mohrland 1985 {published data only}
    1. Mohrland JS, Porter JM. Smith EA.Belch J.Simms MH. A multiclinic, placebo‐controlled, double‐blind study of prostaglandin E1 in Raynaud's syndrome. Annals of the Rheumatic Diseases 1985;44(11):754‐60. - PMC - PubMed
Torley 1991 {published data only}
    1. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, Englert H, Dormandy JA, Watson HR. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Annals of the Rheumatic Diseases 1991;50(11):800‐4. - PMC - PubMed
van den Hoogen 1994 {published data only}
    1. Hoogen, F. H.J., van de Putte,L.B.A. Treatment of systemic sclerosis. 637‐641. - PubMed
Vayssairat 1996 {published data only}
    1. Vayssairat M. Controlled Multicenter Double Blind Trial of an Oral Analog of Prostacyclin in the Treatment of Primary Raynaud's Phenomenon. Journal of Rheumatology 1996;23:1917‐20. - PubMed
Wise 1994 {published data only}
    1. Wise RA, Wigley F. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. Journal of Rheumatology 1994;21(1):80‐3. - PubMed

References to studies awaiting assessment

Cordioli 1992 {published data only}
    1. Cordioli F, Virgilio S, Ghirardi R, Martinelli M. Effetti della terapia a lungo termine con iloprost sul fenomeno di Raynaud nella sclerosi sistemica progressiva. Minerva Medica 1992;83:739‐44. - PubMed

Additional references

ARA 1980
    1. ARA Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis and Rheumatism 1980;23:581‐590. - PubMed
Cohen 1988
    1. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Hillside, New Jersey: Lawrence Erlbaum Associates, Inc. 1988:21‐34.
Dickersin 1994
    1. Dickersin K. , Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286‐91. - PMC - PubMed
Jadad 1996
    1. Jadad A. , Moore A., Carrol D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Medsger 1985
    1. Medsger TA Jr. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: McCarty DJ editor(s). Arthritis and Allied Conditions. 10th Edition. Philadelphia: Lea and Febiger, 1985:994‐1036.
Petitti 1994
    1. Petitti D. Meta‐analysis, decision analysis, and cost‐effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994:90‐114.

Publication types

MeSH terms